Ursula Matulonis

Ursula Matulonis is Chief of Gynecologic Oncology at Dana-Farber and an international authority on fallopian tube carcinoma, primary peritoneal carcinoma, and ovarian cancer. She has led multiple landmark PARP inhibitor clinical trials and has contributed to understanding that fallopian tube and primary peritoneal carcinomas, though treated similarly to high-grade serous ovarian cancer, may have distinct BRCA mutation frequencies and HRD patterns. She has been a principal investigator on olaparib, niraparib, and rucaparib maintenance trials and leads studies on PARP inhibitor combinations and resistance mechanisms.